Expression of CD20, CD46, CD55, and CD59 according to response to rituximab treatment
| Antigen . | MCF . | P . | ||
|---|---|---|---|---|
| NR (N = 10) . | PR (N = 11) . | CR (N = 8) . | ||
| CD20 | 245.8 ± 97 | 229.0 ± 74 | 171.2 ± 64 | .150 |
| (223) | (218) | (171) | ||
| CD46 | 26.4 ± 7.1 | 21.9 ± 6.5 | 29.9 ± 14.1 | .197 |
| (25.9) | (22.9) | (27.5) | ||
| CD55 | 16.4 ± 10.2 | 14.9 ± 7.6 | 23.2 ± 7.3 | .115 |
| (12.2) | (14.7) | (23.6) | ||
| CD59 | 41.6 ± 24.7 | 40.6 ± 31.1 | 30.6 ± 22.8 | .648 |
| (32.2) | (26.9) | (22.7) | ||
| Antigen . | MCF . | P . | ||
|---|---|---|---|---|
| NR (N = 10) . | PR (N = 11) . | CR (N = 8) . | ||
| CD20 | 245.8 ± 97 | 229.0 ± 74 | 171.2 ± 64 | .150 |
| (223) | (218) | (171) | ||
| CD46 | 26.4 ± 7.1 | 21.9 ± 6.5 | 29.9 ± 14.1 | .197 |
| (25.9) | (22.9) | (27.5) | ||
| CD55 | 16.4 ± 10.2 | 14.9 ± 7.6 | 23.2 ± 7.3 | .115 |
| (12.2) | (14.7) | (23.6) | ||
| CD59 | 41.6 ± 24.7 | 40.6 ± 31.1 | 30.6 ± 22.8 | .648 |
| (32.2) | (26.9) | (22.7) | ||
All probability values are 2-sided and are considered statistically significant for P < .05 (single-factor ANOVA). Plus-minus values are means ± SD. Values in parentheses are medians.